FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132020152> ?p ?o ?g. }

• W3132020152 endingPage "48" @default.
• W3132020152 startingPage "PS10" @default.
• W3132020152 abstract "Abstract Background: CDK 4/6 inhibitors in patients (pts) with HR+/HER2- ABC has led to significant improvements in clinical outcomes, however our understanding of the impact of these treatments on CV health is unknown. Gains in overall survival should not be offset by increased CV morbidity and mortality; a particular concern given the shared risk factors for both breast cancer and CV disease. Objective: The aim of this study was to describe patient characteristics, treatment patterns and cardiovascular risk factors and disease in pts with ABC treated with endocrine therapy (ET) or ET + CDK 4/6 inhibitor. Methods: We retrospectively studied pts with HR+/HER2- ABC who were receiving first line endocrine therapy. Post-menopausal (PM) women, pre-menopausal women on ovarian suppression (OS), and men were included. Two cohorts were included: Group A - treated with ET alone (2012-2014; prior to US approval of CDK 4/6 inhibitors) and Group B - treated with ET+ CDK 4/6 inhibitor (2015-2017). The following data was extracted from Duke University Health System’s electronic medical record (EPIC) and entered into a REDCap database: demographics, baseline cardiovascular risk factors, and co-morbidities. Pt characteristics are summarized using medians and interquartile ranges for continuous variables and categorical descriptions are summarized using frequencies and percentages. Results: In total 103 patients were included with 57 in Group A (ET alone) and 46 in Group B (ET + CDK 4/6 inhibitor). Median age was 62.0 and 63.5 years in Group A and B, respectively. Fifty-three (93%) of pts in Group A were PM women compared to 37 (80%) PM women and 1 (3%) male in Group B. The groups seemed to be similar in terms of race (white 70% vs 72%), baseline body mass index (28.2 vs 27.6), baseline systolic blood pressure (132.0 vs 135.5) and diastolic blood pressure (79.0 vs 77.5). Similarly, the groups seemed to be similar in baseline hypertension (68% vs 62%); diabetes (23% vs 24%); Hemoglobin A1c (7.2% vs 6.4%) or family history of CV disease (56% vs 55%), Group A versus Group B, respectively. There were slightly more current/past smokers in Group B than Group A (48% vs 35%) and more pts in Group A with a history of hyperlipidemia relative to Group B (52% vs 31%). Conclusions: In this retrospective descriptive cohort study there seemed to be no differences in demographics or baseline CV risk factors between the ET and ET + CDK 4/6 inhibitor cohorts with the exception of more baseline hyperlipidemia in the ET cohort. This might suggest that baseline CV risk factors did not dissuade practioners from prescribing ET + CDK 4/6 inhibitor therapy. We plan to expand our cohort to collect information on type and duration of ET and CDK 4/6 inhibitors, reason for treatment discontinuation, and CV events (eg heart failure, arrhythmias, stroke, myocardial infarction), to better understand the impact that cardiovascular risk factors have on outcomes in breast cancer patients taking ET+ CDk 4/6 inhibitor. Table 1: Demographics and CV risk factors in ABC patients treated with ET or ET + CDK4/6 inhibitor Median (IQR) unless otherwise indicatedGroup A ET (n=57)Group B ET+ CDK 4/6 inhibitor (n=46)Age median (range)62.0 (27-84)63.5 (30-82)Menopausal status, n (%) Post menopausal Premenopausal + OS Male53 (93) 4 (7) 037 (80) 8 (17) 1 (3)Race, n (%) White Other40 (70) 17 (30)33 (72) 13 (28)Type of Insurance, n (%) Private Medicare Medicare and Private Medicaid Medicaid and Medicare Vererans Sponsored Self-Pay Unknown19 (33) 14 (25) 16 (28) 1 (2) 4 (7) 0 3 (5) 019 (41) 4 (9) 15 (33) 1 (2) 4 (9) 1 (2) 0 2 (4)BMI (kg/m2)28.2 (24.9, 30.6)27.6 (24.4, 34.5)Baseline BP (mmHg) Systolic Diastolic132.0 (118.0, 145.0) 79.0 (73.0, 84.0)135.5 (124.0, 149.0) 77.5 (72.0, 84.0)HgbA1c (%)7.2 (6.4, 7.4)6.4 (5.4, 6.4)CVRF, n (%) Hypertension Diabetes FH CVD Current/past smokers Hyperlipidemia36 (68) 13 (23) 28 (56) 20 (35) 29 (52)28 (62) 11 (24) 22 (55) 22 (48) 14 (31)OS = ovarian suppression; BMI = body mass index; BP = blood pressure; HgbA1c = hemoglobin A1c; CVRF = cardiovascular risk factors; FH = family history; CVD = cardiovascular disease; IQR = Interquartile range Citation Format: Susan Dent, Gloria Broadwater, Terry Hyslop, Kevin Oeffinger, Michel Khouri, Sanjeev Balu, Gretchen Kimmick. Cardiovascular (CV) risk profile in patients with estrogen receptor (ER) positive HER2 negative advanced breast cancer (ABC): A retrospective cohort study (CAREB) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS10-48." @default.
• W3132020152 created "2021-03-01" @default.
• W3132020152 creator A5019554240 @default.
• W3132020152 creator A5036509904 @default.
• W3132020152 creator A5046359837 @default.
• W3132020152 creator A5059225709 @default.
• W3132020152 creator A5061721402 @default.
• W3132020152 creator A5062031844 @default.
• W3132020152 creator A5078465445 @default.
• W3132020152 date "2021-02-15" @default.
• W3132020152 modified "2023-09-27" @default.
• W3132020152 title "Abstract PS10-48: Cardiovascular (CV) risk profile in patients with estrogen receptor (ER) positive HER2 negative advanced breast cancer (ABC): A retrospective cohort study (CAREB)" @default.
• W3132020152 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps10-48" @default.
• W3132020152 hasPublicationYear "2021" @default.
• W3132020152 type Work @default.
• W3132020152 sameAs 3132020152 @default.
• W3132020152 citedByCount "0" @default.
• W3132020152 crossrefType "journal-article" @default.
• W3132020152 hasAuthorship W3132020152A5019554240 @default.
• W3132020152 hasAuthorship W3132020152A5036509904 @default.
• W3132020152 hasAuthorship W3132020152A5046359837 @default.
• W3132020152 hasAuthorship W3132020152A5059225709 @default.
• W3132020152 hasAuthorship W3132020152A5061721402 @default.
• W3132020152 hasAuthorship W3132020152A5062031844 @default.
• W3132020152 hasAuthorship W3132020152A5078465445 @default.
• W3132020152 hasConcept C119060515 @default.
• W3132020152 hasConcept C121608353 @default.
• W3132020152 hasConcept C126322002 @default.
• W3132020152 hasConcept C143998085 @default.
• W3132020152 hasConcept C167135981 @default.
• W3132020152 hasConcept C530470458 @default.
• W3132020152 hasConcept C71924100 @default.
• W3132020152 hasConcept C72563966 @default.
• W3132020152 hasConceptScore W3132020152C119060515 @default.
• W3132020152 hasConceptScore W3132020152C121608353 @default.
• W3132020152 hasConceptScore W3132020152C126322002 @default.
• W3132020152 hasConceptScore W3132020152C143998085 @default.
• W3132020152 hasConceptScore W3132020152C167135981 @default.
• W3132020152 hasConceptScore W3132020152C530470458 @default.
• W3132020152 hasConceptScore W3132020152C71924100 @default.
• W3132020152 hasConceptScore W3132020152C72563966 @default.
• W3132020152 hasIssue "4_Supplement" @default.
• W3132020152 hasLocation W31320201521 @default.
• W3132020152 hasOpenAccess W3132020152 @default.
• W3132020152 hasPrimaryLocation W31320201521 @default.
• W3132020152 hasRelatedWork W2061253854 @default.
• W3132020152 hasRelatedWork W2224319365 @default.
• W3132020152 hasRelatedWork W2315085516 @default.
• W3132020152 hasRelatedWork W2603773853 @default.
• W3132020152 hasRelatedWork W2971392718 @default.
• W3132020152 hasRelatedWork W3037686638 @default.
• W3132020152 hasRelatedWork W3162511055 @default.
• W3132020152 hasRelatedWork W3208090289 @default.
• W3132020152 hasRelatedWork W3210359220 @default.
• W3132020152 hasRelatedWork W4255376461 @default.
• W3132020152 hasVolume "81" @default.
• W3132020152 isParatext "false" @default.
• W3132020152 isRetracted "false" @default.
• W3132020152 magId "3132020152" @default.
• W3132020152 workType "article" @default.